Amblyotech Overview

  • Founded
  • 2013

Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

Amblyotech General Information

Description

Developer of medical modalities platform designed to offer novel medical treatments for treating amblyopia and other ocular disorders. The company's platform uses active gaming and passive video technology with 3-D glasses, training the eyes to work together to view an image in full, enabling clients to access revolutionary treatment for ocular disorders.

Contact Information

Website
www.amblyotech.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Casinos and Gaming
Entertainment Software
Acquirer
Novartis
Primary Office
  • 77 East Missouri Avenue
  • Unit 67
  • Phoenix, AZ 85012
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amblyotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 01-Apr-2020 00000 Completed Generating Revenue
3. Later Stage VC 24-Jan-2020 00000 00000 Completed Generating Revenue
2. Later Stage VC 24-Jul-2019 $150K Completed Generating Revenue
1. Accelerator/Incubator 01-May-2016 $150K $150K 000 Completed Generating Revenue
To view Amblyotech’s complete valuation and funding history, request access »

Amblyotech Patents

  • 8

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Amblyotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4099972-A1 Method of improving stereoacuity using an interval-based protocol Pending 07-Feb-2020 000000000
US-20230149249-A1 Method of improving stereoacuity using an interval-based protocol Pending 07-Feb-2020 000000000
EP-3709862-A4 Method and apparatus for treating diplopia and convergence insufficiency disorder Pending 24-Nov-2017 000000000
US-20190159956-A1 Method and apparatus for treating diplopia and convergence insufficiency disorder Pending 24-Nov-2017 000000000 0
AU-2018373510-A1 Method and apparatus for treating diplopia and convergence insufficiency disorder Pending 24-Nov-2017 A61B3/08
To view Amblyotech’s complete patent history, request access »

Amblyotech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amblyotech Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Jumpstart Health Investors Venture Capital Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
To view Amblyotech’s complete investors history, request access »

Ready to get started?

Request a free trial